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Abstract  
 
Inactivating mutations of the Ten-Eleven translocation (TET)2 gene were first identified in 
myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCL). We 
investigated the presence of TET2 coding sequence mutations and their clinical relevance in a 
large cohort of 190 PTCL patients. TET2 mutations were identified in 40/86 (47%) 
angioimmunoblastic T-cell lymphomas (AITL), 22/58 (38%) peripheral T-cell lymphomas, 
not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities except 2/10 
enteropathy-associated T-cell lymphoma. 
Among PTCL-NOS, a heterogeneous group of lymphoma comprising cases likely to derive 
from T helper follicular (TFH) cells similarly to AITL, TET2 mutations were more frequent 
when PTCL-NOS expressed TFH markers and/or had features reminiscent of AITL (58% vs 
24%, p=0.01). In AITL and PTCL-NOS subgroups, TET2 mutations were associated with an 
advanced stage disease, thrombocytopenia, high International Prognostic Index scores, and a 
shorter progression free survival. 
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Introduction  
Inactivating mutations of the Ten-Eleven translocation (TET)2 gene were first identified in 
myeloid malignancies
1,2
. TET2 encodes a 2 oxoglutarate/Fe2+ dependent oxygenase that 
catalyses the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine
3-5
, and its 
inactivation in mouse results in expansion of the hematopoietic progenitor cells and in 
pleiotropic abnormalities affecting both myeloid and lymphoid lineages
6-8
. Recently, TET2 
mutations have been reported in human lymphomas with a higher frequency in T-cell than in 
B-cell-derived neoplasms (12% versus 2%)
7,9
.  Among peripheral T-cell lymphomas (PTCL), 
the mutations identified were almost exclusively in angioimmunoblastic T-cell lymphoma 
(AITL) and PTCL, not otherwise specified (PTCL-NOS) subtypes, the two most common 
PTCL entities in western countries
10
.  These mutations were demonstrated in tumor cells, with 
evidence that they may be acquired either in early CD34+ progenitors or at later steps of 
lymphoid development
7
. 
Here, we extend the analysis of TET2 mutations to a larger independent series of PTCL 
samples, with an attempt to correlate the mutational status to pathological features and clinical 
outcome.  
 
Materials and methods 
Patients and tumour samples 
A series of 190 PTCL patients with frozen lymphoma samples available at diagnosis were 
selected within the framework of a multicentric T-cell lymphoma consortium (Tenomic). The 
study was approved by the local ethic committee (CPP Ile de France IX= 08-009). Clinical 
data were retrospectively collected. All cases were reviewed and a consensus diagnosis was 
made at multihead microscope by 3 hematopathologists, according to the criteria of the 2008 
WHO classification
11
.  
 4 
Within PTCL-NOS, a group without typical morphology of AITL but expressing TFH markers 
(PD1, BCL6 and/or CXCL13) and/or having some other features reminiscent of AITL [i.e. 
presence of 2 of the following criteria: CD20-positive large B-cells, EBV-encoded small 
RNAs(EBER)-positive cells , CD21 and/or CD23 follicular dendritic cell expansion, CD10 
expression]  was  designated "TFH-like" PTCL-NOS. 
 
TET2 genotyping 
DNA was extracted from several frozen tissue sections with morphological control using 
QIAamp DNA mini Kit (Quiagen, LesUlis, France) and an aliquot amplified by linear 
amplification. Analysis of the coding sequences of TET2 was performed by direct sequencing 
of the PCR fragments and candidate mutations were confirmed by sequencing an independent 
PCR product amplified from native genomic DNA, as previously described
7
. Frameshift, 
nonsense mutations, mutations in splice site, and missense mutations (only those affecting the 
evolutionary conserved regions of the protein) were considered. Single nucleotide 
polymorphisms (SNP) either previously published or recorded in the National Center for 
Biotechnology Information SNP database were excluded. 
 
Statistical analysis 
Continuous and dichotomic variables were compared with the Wilcoxon sum rank test or 
Cochrane Armitage and Khi-2 or Fisher’s exact tests. Overall survival (OS) and progression-
free survival (PFS) were estimated using the Kaplan-Meier method and compared with the log 
rank test. All tests were two-sided and P values <0.05 were considered significant. 
 
Results and Discussion 
TET2 mutations were found in 64/190 samples at diagnosis (34%). The frequency of TET2 
mutations was extremely variable according to the diagnosis category. TET2 mutations were 
 5 
present in 40/86 (47%) AITL, in 22/58 (38%) PTCL-NOS and in 2/10 (20%) enteropathy-
associated T-cell lymphoma. By contrast, no mutation was observed in any of the 18 
anaplastic large cell lymphomas (12 ALK-positive, 6 ALK-negative), the 12 extranodal NK/T 
lymphomas, nasal-type and the 6 hepatosplenic T-cell lymphomas tested (Table 1).  
Interestingly, and in accordance with the previous report
7
 the highest frequency of 
mutations was found in AITL, which is thought to derive from TFH cells normally present in 
germinal centers
12-14
. Within the large group of PTCL-NOS, it is also now recognized that a 
subset has “TFH-like” features in the form of a molecular profile bearing imprints of TFH cell 
signature, the expression of TFH-associated molecules
15-17
 and/or overlapping pathological 
features 
16
. Thus, we questioned whether TET2 mutations correlated with TFH-like features in 
PTCL-NOS. Among the 58 PTCL-NOS in our series, 24 were classified as "TFH-like" PTCL-
NOS. TET2 mutations were present in 14/24 (58%) of the TFH-like PTCL subgroup compared 
to 8/34 (22%) in those lacking AITL features and TFH-markers. Therefore, TET2 mutations in 
PTCL appear to correlate with TFH derivation, i.e occur at higher frequency in AITL and TFH-
like PTCL-NOS, than in non-TFH-like PTCL-NOS and other PTCL entities (49% vs 12,5%, 
p<0.0001).  
Among the 64 PTCL patients with TET2 mutations, 37 had single mutations and 27 had 2 or 
more mutations. TET2 mutations were mainly insertions/deletions generating frameshifts and 
nonsense mutations, similar to those found in myeloid malignancies (Table S1). Eighteen of 
19 missense mutations were predicted as probably damaging by the polyphen software 
(http://genetics.bwh.harvard.edu/pph2/) and one as possibly damaging. For three mutated 
patients with available biopsy at relapse, an identical pattern of TET2 mutations was found in 
paired samples (Figure S1), suggesting that TET2 mutations are associated with the main 
driving clone. 
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When focusing on AITL and PTCL-NOS patients (n=144), 62 patients had TET2 
mutations and 82 were TET2 wildtype. Clinical factors associated with TET2 mutated status 
(Table 2 and Figure S2) were advanced stage disease (p=0.02), increased number of involved 
extranodal sites (p=0.017), presence of B symptoms (p=0.02), thrombocytopenia (p=0.04), 
high International Prognosis Index (IPI) (p=0.028) and Prognosis Model for PTCL-NOS 
(PIT)
18
 (p=0.025) scores, indicating that TET2 mutations are associated with adverse clinical 
parameters at presentation. Despite incomplete clinical data and heterogeneous therapies in 
this multicentric retrospective cohort, anthracyclin-based chemotherapy was the most 
common regimen in both mutated and non-mutated groups (73% and 70% respectively). In 
this retrospective study, TET2-mutated patients with AITL or PTCL-NOS appeared to have a 
shorter PFS (p=0.04) than TET2-wildtype patients, but no significant difference in OS was 
observed (p=0.1) (Figure S2). The association between TET2 mutations, poor prognosis 
clinical parameters and outcome was even stronger when focusing on the group of patients 
with AITL and TFH-like PTCL-NOS. In this group, TET2 mutations were associated with a 
shorter PFS (p=0.022) and a trend to a shorter overall survival (p=0.058) (Table S2 and 
Figure S3) 
We recently reported recurrent IDH2 mutations in AITL
19
. These mutations alter IDH 
enzymatic function and may result in the functional inactivation of TET protein activity 
20
.  In 
acute myeloid leukemia, IDH and TET2 mutations are reported mutually exclusive 
20
. Of the 
31 AITL samples from the current study also analysed for IDH2 mutations
19
, 6 cases 
disclosed both IDH2 and TET2 mutations, 2 cases were IDH2 mutated/TET2 wildtype and 10 
cases were TET2 mutated/IDH2 wildtype, indicating that both mutations can accumulate in 
AITL. Ultimately, both IDH2 and TET2 mutations, recurrent in AITL and in TFH-derived 
PTCL may deregulate the control of chromatin structure. This situation may be reminiscent of 
that observed in B-cell lymphomas, in which mutations of several genes involving epigenetic 
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changes and chromatin remodelling, such as CREEBP, EP300
21
, EZH2
22
, MLL2 or MEF2B
23
 
have recently been described. 
In addition to similarities in their ontogeny, AITL and a subset of TFH-like PTCL share 
common oncogenic alterations including TET2 abnormalities, further supporting their close 
relationship. The strong association between TET2 mutations, AITL and TFH-like PTCL may 
provide molecular rationale to merge together AITL and PTCL-NOS expressing TFH markers 
as previously suggested
15,16
 and to refine the spectrum of AITL. Overall, the identification of 
frequent TET2 mutations in AITL and other TFH-related PTCL extends the importance of 
epigenetic alterations in lymphomagenesis. These results suggest that, in these diseases in 
which conventional chemotherapies are ineffective
24
 in most patients, the use of new agents, 
such as demethylating agents should be considered. 
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Table 1: TET2 mutations in the different PTCL entities.  
 
PTCL-NOS: PTCL, not otherwise specified, AITL: angioimmunoblastic T-cell lymphoma, 
ALCL: anaplastic large cell lymphoma, HSTL: hepatosplenic T-cell lymphoma, EATL: 
enteropathy-associated T-cell lymphoma, Extranodal NK/T: extranodal NK/T-cell lymphoma, 
nasal-type. 
(°)TET2 mutations were found in 2 intestinal tissue samples diagnosed as EATL and (*) in 3 
other extranodal tissue samples (1 skin, 1 spleen, 1 liver) diagnosed as PTCL-NOS 
 
PTCL entities  TET2 mutation 
  N N % 
AITL 86 40 47% 
PTCL NOS * 58 22 38% 
       TFH-like 24 14 58% 
       Others 34 8 24% 
ALCL 18 0 0% 
EATL ° 10 2  20% 
Extranodal NK/T 12 0 0% 
HSTL 6 0 0% 
    
Total 190 64 34% 
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Table 2: Clinical data according to TET2 status in AITL and PTCL-NOS patients 
1 
: Fisher exact test,
 2
 : Wilcoxon sum rank test, 
3
 :Cochran Armitage test, 
4
: log rank test 
 
 TET2 mutation TET2 WT  
N 62  82   
Sex/ gender      
       Male 38 61% 43 52% p=0.18
1
 
       Female 24 39% 39 48%  
Age (median) 67  65  p=0.3
2
 
Stage      
1 0 0% 4 5% p=0.028
3
 
2 0 0% 3 4%  
3 11 21% 17 23%  
4 42 79% 49 67%  
Number of extra nodal localizations (median) 2  1  p=0.056
2
 
Lactate dehydrogenase      
Elevated 41 76% 46 65% p=0,24
1
 
Normal 13 24% 25 35%  
Hemoglobin      
≥10g/dL 35 74% 33 60% p=0.141 
<10g/dL 12 26% 22 40%  
Platelet count      
≥150000/mm3 34 72% 48 89% p=0.041 
<150000/mm3 13 28% 6 11%  
Direct Coombs test      
Positive 14 52% 13 43% p=0.6
1
 
Negative 13 48% 17 57%  
Hypergammaglobulinemia      
Yes 11 32% 12 33% p=1
1
 
No 23 68% 24 67%  
B symptoms      
Yes 40 78% 38 58% p=0.028
1
 
No 11 22% 27 42%  
Performance status      
0-1 22 44% 41 62% p=0.06
1
 
2-4 28 56% 25 38%  
International Prognosis Index      
0 0 0% 4 6% p=0.0062
2
 
1 2 4% 4 6%  
2 8 16% 11 16%  
3 10 20% 22 33%  
4 19 37% 23 34%  
5 12 24% 3 4%  
Prognosis Model for PTCL
18
      
0 2 5% 4 9% p=0.0045
2
 
1 3 7% 11 24%  
2 9 21% 13 29%  
3 18 43% 13 29%  
4 10 24% 4 9%  
Treatment      
Anthracycline based regimen 37 69% 40 58% P=0,5
1
 
Anthracycline based regimen  and frontline 
transplantation 
2 4% 8 12% 
 
Other combination of chemotherapy 7 13% 8 12%  
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Single agent chemotherapy 5 9% 7 10%  
Palliative treatment 3 6% 6 9%  
5 years OS 28%  31%  p=0.11
4
 
5 years PFS 10%  21%  p=0.047
4
 
 
 
 
 
  
